Hematologic Malignancies Clinical Trial
Official title:
Exercise Capacity, Physical Activity Level and Quality of Life in Newly Diagnosed Hematologic Malignant Patients
Hematologic malignancies are neoplasms that affect the blood, bone marrow, and lymph nodes.
Hematological malignancies are the most common forms of leukemia, lymphoma, and myeloma, with
numerous subtypes. The general symptoms of leukemia are fatigue, increased susceptibility to
infection, bleeding, and the formation of bruises easily. Typical lymphoma symptoms are night
sweats and involuntary weight loss, recurrent fever, fatigue, and itching. Myeloma patients
often have bone pain, fatigue, anemia, hypercalcemia or infection symptoms.
Adverse effects of hematologic malignancies and treatments cause abnormality in physical
function and quality of life. Treatments such as chemotherapy, radiotherapy and hematopoietic
stem cell transplantation, which may have side effects on the body systems are used in early
or late period. The most common side effect due to chemotherapy is fatigue. Vomiting, weight
loss, anemia, depression, decreased aerobic capacity, loss of muscle strength, decreased
physical functioning and deterioration in the quality of life are indirect side effects seen
in patients.
In the literature, side effects of hematological malignancies have been investigated after
treatment in patients. However, no study investigated exercise capacity, quality of life,
physical activity level and pulmonary functions on newly diagnosed hematologic malignant
patients. Therefore, the investigators aimed to compare aforementioned outcomes in newly
diagnosed hematologic malignant patients and healthy controls.
According to sample size calculation 30 newly diagnosed hematologic malignant patients and 30 healthy individuals will be included. Before treatment submaximal exercise capacity, physical activity, quality of life, pulmonary functions, respiratory and peripheral muscle strength, respiratory muscle endurance, dyspnea and fatigue perception, anxiety and depression will be evaluated. Primary outcome measurements are exercise capacity, physical activity, quality of life, secondary outcomes are respiratory and peripheral muscle strength, respiratory muscle endurance, pulmonary functions, dyspnea and fatigue perception, anxiety and depression. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05433090 -
An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies
|
N/A | |
| Completed |
NCT00061620 -
Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies
|
Phase 1 | |
| Enrolling by invitation |
NCT02473757 -
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
|
||
| Not yet recruiting |
NCT06296368 -
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
|
N/A | |
| Recruiting |
NCT02032446 -
Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01203722 -
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02884375 -
Elderly CAncer Patient
|
N/A | |
| Completed |
NCT00780052 -
Infusional C-myb ASODN in Advanced Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT04098393 -
Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation
|
Phase 1 | |
| Recruiting |
NCT06028828 -
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
| Completed |
NCT04538599 -
RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT03609827 -
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
|
||
| Completed |
NCT01380756 -
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT05849207 -
Post-Transplant Cyclophosphamide in Patients Aged >/= 70 Years Undergoing Haploidentical Transplant
|
Phase 1 | |
| Not yet recruiting |
NCT05028478 -
A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02494258 -
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
|
Phase 2 | |
| Active, not recruiting |
NCT02600208 -
Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device
|
Phase 2/Phase 3 | |
| Completed |
NCT02145403 -
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT01949545 -
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment
|
Phase 1 | |
| Completed |
NCT01930981 -
Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life
|
N/A |